natgillin/translations-raw huggingface dataset:
See section 6.5 for the number of doses per container.
Glejte poglavje 6.5 za število odmerkov na vsebnik.
The study was not designed to demonstrate efficacy in subgroups, and the number of subjects ≥ 85 years of age was not sufficient to demonstrate efficacy in this age group.
Študija ni bila načrtovana za dokaz učinkovitosti pri podskupinah, število vključenih, starih 85 let in več, pa ni bilo zadostno, da bi dokazali učinkovitost pri tej starostni skupini.
As the benefit of vaccination is high in this group of infants, vaccination should not be withheld or delayed.
Ker je korist cepljenja v tej skupini dojenčkov velika, se cepljenja ne sme izpustiti ali odložiti.
The vaccine works by helping the body to make its own antibodies, which protect you or your child against these diseases.
Cepivo deluje tako, da spodbudi tvorbo telesu lastnih protiteles, ki vas ali vašega otroka ščitijo pred temi boleznimi.
Children < 5
Otroci < 5
Prevenar 13 is stable at temperatures up to 25°C for four days.
Cepivo Prevenar 13 je stabilno pri temperaturah do 25 °C 4 dni.
** p<0.005 to cover 6A where p=0.002
** p < 0,005 z upoštevanjem 6A, kjer je p = 0,002.
These data are intended to guide health care professionals in case of temporary temperature excursions.
Ti podatki služijo kot priporočila za zdravstvene delavce v primeru začasnih odstopanj temperature.
The study demonstrated that safety and immunogenicity were generally comparable with observations made in studies of intramuscular administration.
Študija je pokazala, da sta bili varnost in imunogenost na splošno primerljivi z opažanji v študijah intramuskularne uporabe cepiva.
According to official recommendations in your country, an alternative schedule may be used by your healthcare provider.
V skladu z uradnimi priporočili v vaši državi lahko vaš ponudnik zdravstvenih storitev uporabi tudi drugačno shemo cepljenja.
Individuals with the conditions described below have an increased risk of pneumococcal disease.
Posamezniki s spodaj opisanimi stanji so izpostavljeni povečanemu tveganju za pnevmokokne bolezni.
2005 data.
Podatki iz leta 2005.
The CAPiTA study enrolled volunteers ≥ 65 years of age whose demographic and health characteristics may differ from those seeking vaccination.
V študijo CAPiTA so bili vključeni prostovoljci, stari 65 let in več, katerih demografske in zdravstvene značilnosti se lahko razlikujejo od tistih, ki se želijo cepiti.
This is a multidose presentation.
To je večodmerna oblika.
The clinical relevance of the lower GMCs and GMTs is currently unknown.
Klinični pomen nižjih ravni GMC in GMT zaenkrat ni znan.
Unvaccinated Children (12-23 months)
Necepljeni otroci (12-23 mesecev)
Confidence intervals (CIs) for the ratio are back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures.
Intervali zaupanja (IZ) za razmerje so povratne transformacije intervala zaupanja, zasnovanega na Studentovi tporazdelitvi za srednjo vrednost razlike logaritmov merjenj.
• You will be told when your child should come back for the next injection.
• Povedali vam bodo, kdaj mora otrok prejeti naslednji odmerek.
For adjuvant, see section 2.
Za adjuvanse glejte poglavje 2.
2004 data.
Podatki iz leta 2004.
Decreased appetite
zmanjšan apetit
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
Podrobne informacije o cepivu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu.
In accordance with Article 114 Directive 2001/83/EC, the official batch release will be undertaken by a state laboratory or a laboratory designated for that purpose.
V skladu s členom 114 Direktive 2001/83/ES z vsemi dopolnitvami in spremembami, serijo uradno sprosti državni laboratorij ali laboratorij, določen v ta namen.
First episode of VT-IPD
Prva epizoda VT-IPD
drowsiness; restless sleep
zaspanost in nemirno spanje
Preterm infants (<37 weeks gestation)
Nedonošenčki (< 37 tednov nosečnosti)
These observations are consistent with adequate priming (the induction of immunologic memory).
Ta opažanja so v skladu z ustreznim osnovnim cepljenjem (indukcija imunološkega spomina).
A reduction in carriage was also seen for serotype 3 (2.5% vs 1.1%; p=0.1).
Zmanjšanje nosilstva so opazili tudi za serotip 3 (2,5 % v primerjavi z 1,1 %; p = 0,1).
Bacteria can be responsible for 60-70% of clinical episodes of AOM.
Bakterije so lahko odgovorne za od 60 do 70 % kliničnih epizod akutnega vnetja srednjega ušesa.
Other adverse events previously observed in infants and children 6 weeks to 5 years of age may also be applicable to this age group but were not seen in this study possibly due to the small sample size.
Drugi neželeni učinki, opaženi pri dojenčkih in otrocih, starih od 6 tednov do 5 let, so lahko prisotni tudi pri tej starostni skupini, vendar jih v tej študiji niso opazili, verjetno zaradi majhne velikosti vzorca.
It will not protect against other infectious agents that can cause ear infections.
Ne zaščiti pa pred drugimi povzročitelji, ki lahko povzročijo okužbe ušes.
The frequency is defined as follows: very common ( 1/10), common ( 1/100 to < 1/10), uncommon ( 1/1,000 to < 1/100), rare ( 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from available data).
Pogostnost je opredeljena kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), neznana (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti).
Convulsions (including febrile convulsions)
konvulzije (vključno z vročinskimi konvulzijami)
Immune responses to the additional 6 serotypes were also measured.
Ovrednotili so tudi imunske odzive na 6 dodatnih serotipov.
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).
Študije na živalih ne kažejo neposrednega ali posrednega škodljivega vpliva na sposobnost razmnoževanja (glejte poglavje 5.3).
In this study, reductions of S. pneumoniae serotypes 19A, 19F, and 6A not susceptible to a number of antibiotics were documented.
V tej študiji so dokumentirali zmanjšanja S. pneumoniae serotipov 19A, 19F in 6A, ki niso bili dovzetni za številne antibiotike.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Od zdravstvenih delavcev se zahteva, da poročajo o kateremkoli domnevnem neželenem učinku cepiva na nacionalni center za poročanje, ki je naveden v Prilogi V.
• Worsening or new pain in your joints, worsening or new pain in your muscles
• poslabšanje ali novonastala bolečina v sklepih, poslabšanje ali novonastala bolečina v mišicah
NNV also incorporates the length of the trial or duration of protection and is calculated as 1 divided by the product of the IRR and duration of protection (or length of trial) (=1/(IRR × duration).
Poleg tega NNV vključuje tudi dolžino preskušanja ali trajanje zaščite in se izračuna kot 1, deljeno z zmnožkom IRR in trajanjem zaščite (ali dolžino preskušanja) (= 1/(IRR × trajanje).
Significant incidence reductions were also observed in older age groups who had not been vaccinated with Prevenar 13 (indirect effect).
Pomembna zmanjšanja incidence so ugotovili tudi pri starejših skupinah, ki niso bile cepljene s cepivom Prevenar 13 (posredni učinek).
See also section 4.
Glejte tudi poglavje 4.
Pharmacotherapeutic group: vaccines, pneumococcal vaccines; ATC code: J07AL02
Farmakoterapevtska skupina: cepiva, cepiva proti pnevmokoknim infekcijam; oznaka ATC: J07AL02.
There was no reduction seen in serotype 3 and for serotype 5 the colonization was too infrequent to assess impact.
Za serotip 3 niso opazili zmanjšanja, pri serotipu 5 pa je bila kolonizacija preveč redka, da bi lahko ocenili vpliv.
Other medicines/vaccines and Prevenar 13
Druga zdravila/cepiva in cepivo Prevenar 13
Table 2: Serotype specific number of cases and incidence reductions of IPD in 2013/14 compared to 2008/09-2009/10 (2008/10) by age in England and Wales
Preglednica 2: Število primerov in zmanjšanje incidence IPD za vsak serotip v obdobju 2013/14 v primerjavi z obdobjem 2008/09-2009/10 (2008/10) po starosti v Angliji in Walesu Stari < 5 let
• if you or your child is allergic (hypersensitive) to the active substances or to any of the other ingredients in this medicine (listed in section 6) or to any other vaccine that contains diphtheria toxoid.
• če ste vi ali vaš otrok alergični (preobčutljivi) na učinkovine ali katerokoli sestavino tega cepiva (navedeno v poglavju 6) ali na katerokoli drugo cepivo, ki vsebuje davični toksoid.
The immunogenicity after two doses in infants has been documented in four studies.
Imunogenost po cepljenju z dvema odmerkoma pri dojenčkih so dokumentirali v štirih študijah.
Adverse reactions from clinical studies
Neželeni učinki iz kliničnih študij
Therefore the use of Prevenar 13 should be avoided during pregnancy.
Zato se je treba uporabi cepiva Prevenar 13 med nosečnostjo izogibati.
Infants, children, and adolescents previously vaccinated with Prevenar
Dojenčki, otroci in mladostniki, ki so bili predhodno cepljeni s cepivom Prevenar
OPA titres are expressed as the reciprocal of the highest serum dilution that reduces survival of the pneumococci by at least 50 %.
Titri OPA so izraženi kot recipročna vrednost največje razredčitve seruma, ki zmanjša preživetje pnevmokokov za najmanj 50 %.
Local reactions and systemic events were solicited daily after each vaccination for 14 days in 6 studies and 7 days in the remaining study.
Poročila o lokalnih reakcijah in sistemskih učinkih so bila po vsakem cepljenju pridobljena dnevno v obdobju 14 dni v 6 kliničnih študijah in v obdobju 7 dni v sedmi klinični študiji.
S. pneumoniae is the most frequent cause of CAP, and is estimated to be responsible for approximately 30% of all CAP cases requiring hospitalisation in adults in developed countries.
Najpogostejši vzrok CAP je S. pneumoniae, ki v razvitih državah povzroči približno 30 % vseh primerov CAP, kjer je potrebna hospitalizacija odraslih bolnikov.
IRR, also referred to as vaccine preventable disease incidence, is the number of cases of vaccine preventable disease per 100,000 person-years of observation.
IRR, ki ga imenujemo tudi incidenca bolezni, ki jo je mogoče preprečiti s cepljenjem, je število primerov bolezni, ki jo je mogoče preprečiti s cepljenjem, na 100.000 oseb-let opazovanja (PYOperson-years of observation).
Invasive Pneumococcal Disease
Invazivna pnevmokokna bolezen
S. pneumoniae is one of the most common causes of bacterial AOM worldwide.
S. pneumoniae je eden najpogostejših vzrokov bakterijskega akutnega vnetja srednjega ušesa po vsem svetu.
Prevenar 13 Relative to PPSV23, 60-64 Years
Prevenar 13 v primerjavi s PPSV23, 60-64 let
Immune responses in Special Populations
Imunski odzivi pri posebnih populacijah
In this age group, serotypes 1, 3, 5, 6A, 7F, and 19A account for 15.6% to 59.7% of invasive disease, depending on the country, the time period studied, and the use of Prevenar.
V tej starostni skupini serotipi 1, 3, 5, 6A, 7F in 19A povzročajo od 15,6 % do 59,7 % invazivnih bolezni, odvisno od države, preučevanega časovnega obdobja in uporabe cepiva Prevenar.
Different injectable vaccines should always be given at different vaccination sites.
Različna cepiva za injiciranje je treba vedno injicirati na različna mesta.
During storage, a white deposit and clear supernatant may be observed.
Med shranjevanjem se lahko pojavita bela usedlina in bister supernatant.
Safety in 354 previously unvaccinated children (7 months to 5 years of age) was also assessed.
Varnost je bila ocenjena tudi pri 354 predhodno necepljenih otrocih (starih od 7 mesecev do 5 let).
In Table 6, NNV is a measure that quantifies the number of people that need to be vaccinated in order to prevent one clinical CAP case.
V preglednici 6 je NNV merilo števila ljudi, ki jih je treba cepiti, da preprečimo en primer klinične CAP.
The efficacy results from these studies (for invasive pneumococcal disease, pneumonia, and acute otitis media) are presented below (Table 3).
Rezultati učinkovitosti iz teh študij (za invazivno pnevmokokno bolezen, pljučnico in akutno vnetje srednjega ušesa) so predstavljeni spodaj (preglednica 3).
For all pivotal clinical trials, a serotype-specific opsonophagocytosis assay (OPA) was used as a surrogate to assess potential efficacy against invasive pneumococcal disease and pneumonia.
Pri vseh ključnih kliničnih preskušanjih je bila serotipno specifična opsonofagocitozna analiza (OPA) uporabljena kot nadomestek za oceno morebitne učinkovitosti proti invazivni pnevmokokni bolezni in pljučnici.
oC. Other in-use storage times and conditions are the responsibility of the user.
Za čas shranjevanja in pogoje pred uporabo je odgovoren uporabnik.
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.
Imetnik dovoljenja za promet s cepivom bo izvedel zahtevane farmakovigilančne aktivnosti in ukrepe, podrobno opisane v sprejetem RMP, predloženem v modulu 1.8.2 dovoljenja za promet s cepivom, in vseh nadaljnjih sprejetih posodobitvah RMP.
NNV is not a rate but instead indicates the number of cases prevented for a given number of persons vaccinated.
NNV ne izraža stopnje, temveč število primerov, preprečenih pri danem številu cepljenih oseb.
Burden of disease
Breme bolezni
The immunisation schedules for Prevenar 13 should be based on official recommendations.
Sheme cepljenja s cepivom Prevenar 13 morajo temeljiti na uradnih priporočilih.
The incidence in older, predominantly non-vaccinated children (>5 years) did not change over the duration of the study.
Incidenca pri starejših, večinoma necepljenih otrocih (starejši od 5 let), se v času trajanja študije ni spremenila.
For the 7 common serotypes there were no differences between groups in the proportion of subjects with OPA titres ≥ 1:8.
Za 7 skupnih serotipov niso ugotovili razlik med skupinami, kar se tiče deleža preskušancev s titri OPA ≥ 1:8.
Safety was assessed in 7 clinical studies including 91,593 adults ranging in age from 18 to 101 years.
Varnost je bila ocenjena v 7 kliničnih študijah, v katere je bilo vključenih 91.593 odraslih v starosti od 18 do 101 leta.
23 to 2948
23 do 2.948
Corrected for proportion of samples serotyped, missing age, denominator compared with 2009/10, and for the trend in total invasive pneumococcal disease up to 2009/10 (after which no trend correction was applied).
Popravljeno za delež serotipiziranih vzorcev, manjkajočo starost, imenovalec, primerjan z obdobjem 2009/10, in trend skupne IPD do obdobja 2009/10 (pozneje popravek trenda ni bil uporabljen).
* 95% CI inflated from a Poisson interval based on over-dispersion of 2.1 seen from modelling of 2000-06 pre-Prevenar all IPD data.
* 95 % IZ, ki izhaja iz Poissonovega intervala na podlagi nadrazpršenosti 2,1, ki so jo opazili pri modeliranju vseh podatkov o IPD iz obdobja 2000-06 pred uporabo cepiva Prevenar.
For 6 of the remaining 7 common serotypes, similar rates of NP acquisition were observed in both vaccine groups; for serotype 19F a significant reduction was observed.
Za 6 od preostalih 7 skupnih serotipov so opazili podobno naselitev nosnožrelnega prostora pri obeh cepivih; za serotip 19F pa so opazili pomembno zmanjšanje.
The reported incidence of community-acquired pneumonia (CAP) and IPD in Europe varies by country, increases with age from 50 years and is highest in individuals aged ≥ 65 years.
Poročana incidenca zunajbolnišnične pljučnice (CAP - Community-Acquired Pneumonia) in invazivne pnevmokokne bolezni (IPD - Invasive Pneumococcal Disease) se v Evropi razlikuje od države do države, po 50. letu se povečuje s starostjo in je največja pri posameznikih, starih ≥ 65 let.
Adverse reactions reported in clinical studies or from the postmarketing experience for all age groups are listed in this section per system organ class, in decreasing order of frequency and seriousness.
Neželeni učinki, o katerih so poročali v kliničnih študijah ali v obdobju trženja (za vse starostne skupine), so v tem poglavju navedeni po organskih sistemih po padajoči pogostnosti in resnosti.
Efficacy was demonstrated for the primary and secondary endpoints in the per protocol population (Table 5).
Učinkovitost je bila dokazana za primarni in sekundarna opazovana dogodka v populaciji po protokolu (preglednica 5).
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before receiving this medicine.
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom ali farmacevtom, preden prejmete to cepivo.
6A 7F 19A The serotype in Prevenar with the lowest percent response rate was 6B in study 006 (87.1 %).
6A 7F 19A Serotip v cepivu Prevenar z najmanjšim deležem odziva v študiji 006 je bil 6B (87,1 %).
C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET S CEPIVOM
The use of Prevenar 13 should be determined on the basis of official recommendations taking into consideration the risk of invasive disease and pneumonia in different age groups, underlying comorbidities as well as the variability of serotype epidemiology in different geographical areas.
Uporaba cepiva Prevenar 13 mora temeljiti na podlagi uradnih priporočil, ki upoštevajo tako tveganje invazivne bolezni in pljučnice v različnih starostnih skupinah ter sočasno prisotne bolezni, kot tudi variabilnost epidemiološke razširjenosti serotipov v različnih zemljepisnih predelih.
The most commonly reported adverse reactions in children 6 weeks to 5 years of age were vaccination-site reactions, fever, irritability, decreased appetite, and increased and/or decreased sleep.
Neželeni učinki, o katerih so najpogosteje poročali pri otrocih, starih od 6 tednov do 5 let, so bili reakcije na mestu cepljenja, vročina, razdražljivost, zmanjšan apetit in podaljšan ali skrajšan čas spanja.
Tell your doctor, pharmacist or nurse if you or your child is taking, has recently taken or might take any other medicines, or has recently received any other vaccine.
Obvestite zdravnika, farmacevta ali medicinsko sestro, če vi ali vaš otrok jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katerokoli drugo zdravilo ali če ste bili vi ali vaš otrok pred kratkim cepljeni s katerimkoli cepivom.
If this applies to you or your child, then the vaccination will be postponed until you or your child is feeling better.
V tem primeru bo zdravnik cepljenje odložil, dokler se vi ali vaš otrok ne boste počutili bolje.
It is unknown whether pneumococcal 13-valent conjugate vaccine is excreted in human milk.
Ni znano, ali se 13-valentno pnevmokokno konjugirano cepivo pri človeku izloča v mleko.
Your doctor may ask you to give your child paracetamol or other medicines that lower fever before Prevenar 13 is given.
Zdravnik vam bo morda naročil, da svojemu otroku date paracetamol ali druga zdravila za zniževanje vročine, preden bo dobil cepivo Prevenar 13.
For the six additional serotypes, these values were compared with the lowest response among all of the seven common serotypes in the Prevenar recipients.
Za šest dodatnih serotipov so te vrednosti primerjali z najmanjšim odzivom med vsemi sedmimi skupnimi serotipi pri preskušancih, ki so prejeli cepivo Prevenar.
A post-hoc analysis was used to estimate the following public health outcomes against clinical CAP (as defined in the CAPiTA study, and based on clinical findings regardless of radiologic infiltrate or etiologic confirmation): vaccine efficacy (VE), incidence rate reduction (IRR), and number needed to vaccinate (NNV) (Table 6).
S post-hoc analizo so ocenili naslednje javnozdravstvene izide glede klinične CAP (kot so jo opredelili v študiji CAPiTA in na podlagi kliničnih ugotovitev, ne glede na radiološki infiltrat ali potrditev vzroka): učinkovitost cepiva (UC), zmanjšanje incidence (IRR - incidence rate reduction) in število ljudi, ki jih je treba cepiti (NNV - number needed to vaccinate) (preglednica 6).
• has any present or past medical problems after any dose of Prevenar or Prevenar 13 such as an allergic reaction or problems with breathing.
• po predhodnem cepljenju s katerimkoli odmerkom cepiva Prevenar ali Prevenar 13 kakršnekoli zdravstvene težave, na primer alergijsko reakcijo ali težave z dihanjem.
Hampshire PO9 2NG United Kingdom
Hampshire PO9 2NG Velika Britanija
All serotypes: 73% Vaccine serotypes: 2-dose infant series: 99% Completed schedule:100%
Vsi serotipi: 73 % Serotipi cepiva: shema cepljenja dojenčkov z 2 odmerkoma: 99 % dokončana shema:100 %
Bacteraemic pneumonia (approximately 80% of IPD in adults), bacteraemia without a focus, and meningitis are the most common manifestations of IPD in adults.
Pljučnica z bakteriemijo (približno 80 % primerov IPD pri odraslih), bakteriemija brez žarišča in meningitis so najpogostejše pojavne oblike IPD pri odraslih.
The efficacy of 7-valent Prevenar was evaluated in two major studies - the Northern California Kaiser Permanente (NCKP) study and the Finnish Otitis Media (FinOM) study.
Učinkovitost 7-valentnega cepiva Prevenar so ovrednotili z dvema večjima kliničnima študijama - s severnokalifornijsko študijo Northern California Kaiser Permanente (NCKP) in finsko študijo vnetja srednjega ušesa (FinOM).
Prevenar 13 50-59 Relative to 60-64 Years
Prevenar 13 50-59 let v primerjavi s 60-64 let
The first dose was administered at 3 to 6 months after HSCT.
Prvi odmerek so prejeli od 3 do 6 mesecev po HSCT.
Five clinical studies were conducted in Europe and the USA evaluating the immunogenicity of Prevenar 13 in different age groups ranging from 18-95 years of age.
V Evropi in ZDA so izvedli 5 kliničnih študij, s katerimi so ocenjevali imunogenost cepiva Prevenar 13 pri različnih starostnih skupinah v starosti od 18 do 95 let.
Furthermore, in this study statistically significantly greater OPA GMTs were demonstrated for 10 of the 12 serotypes in common.
Poleg tega so v tej študiji dokazali statistično pomembno večje vrednosti geometričnih sredin titrov (GMT) OPA za 10 izmed 12 skupnih serotipov.
While direct cause-and-effect cannot be inferred from observational analyses of this type, these findings suggest that Prevenar plays an important role in reducing the burden of mucosal disease (AOM and pneumonia) in the target population.
Medtem ko iz tovrstnih opazovalnih analiz ne moremo sklepati na neposreden vzrok in posledico, te ugotovitve kažejo, da ima cepivo Prevenar pri ciljni populaciji pomembno vlogo pri zmanjševanju bremena bolezni sluznic (akutno vnetje srednjega ušesa in pljučnica).
The clinical relevance of the antibody levels elicited by Prevenar 13 in these special populations is unknown.
Klinična pomembnost ravni protiteles, ki jih pri teh posebnih populacijah povzroči cepivo Prevenar 13, ni znana.
There was no carriage of serotypes 1 and 5 observed.
Nosilstva za serotipa 1 in 5 niso opazili.
In children and adolescents aged 6 to 17 years, the incidence of pneumococcal disease is low, however, there is an increased risk of morbidity and mortality in those with underlying comorbidities.
Pri otrocih in mladostnikih, starih od 6 do 17 let, je incidenca pnevmokokne bolezni majhna, vendar pa pri tistih s sočasno prisotnimi boleznimi obstaja povečano tveganje obolevnosti in smrtnosti.
All episodes analysis
Analiza vseh epizod
Prevenar 13, provides protection against 13 types of Streptococcus pneumoniae bacteria, and replaces Prevenar, which provided protection against 7 types.
Cepivo Prevenar 13 nudi zaščito proti 13 tipom bakterije Streptococcus pneumoniae in nadomešča cepivo Prevenar, ki nudi zaščito proti 7 tipom.
What you need to know before you or your child receives Prevenar 13
Kaj morate vedeti, preden boste vi ali vaš otrok prejeli cepivo Prevenar 13
Following the widespread use of Prevenar, the incidence of IPD has been consistently and substantially reduced.
Zaradi razširjene uporabe cepiva Prevenar se je incidenca invazivnih pnevmokoknih bolezni dosledno in znatno zmanjšala.